Research advances in mechanisms of EGFR targeted drugs in hepatocellular carcinoma

Liver cancer, as the most common malignant tumor of the digestive system worldwide, its incidence and mortality rate are increasing year by year. The first-line drugs for hepatocellular carcinoma (HCC) have drug resistance and high toxicity, so there is an urgent need to develop new molecular targeted drugs. Epidermal growth factor receptor (EGFR) is highly expressed in HCC and is involved in related signal transduction pathways, which plays an important role in the development, growth and metastasis of HCC. Therefore, targeted inhibition of EGFR may effectively inhibit the growth and metastasis of HCC. At present, there is limited research on the mechanism of EGFR-targeted drugs in HCC, so this article focuses on the action mechanisms of EGFR-targeted drugs in the treatment of HCC by summarizing the latest research progress, so as to explore their development prospects and provide guidance for clinical treatment.